{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System Cephalothin (1-64 \u03bcg/mL)",
        "BD Phoenix Automated Microbiology System for use with the antimicrobial agent Cephalothin (1-64 \u03bcg/mL) Gram-negative ID/AST or AST only Phoenix panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K060558",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322",
        "K031943"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "May 11, 2006",
    "Summary Letter Received Date": "May 4, 2006",
    "Submission Date": "May 2, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cephalothin"
    ],
    "Specimen Type(s)": [
        "Isolates from pure culture of Gram-negative aerobic and facultative anaerobic bacteria",
        "Isolates from pure culture of Gram-positive bacteria belonging to Staphylococcus, Enterococcus, and Streptococcus"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix Automated Microbiology System"
    ],
    "Method(s)/Technology(ies)": [
        "Broth based microdilution test",
        "Automated susceptibility testing",
        "Redox indicator detection"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Quantitative MIC determination"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Instrument",
        "Software",
        "Broth",
        "Indicator solution",
        "Tray"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System with Cephalothin panels for quantitative antimicrobial susceptibility testing of Gram-negative and Gram-positive bacterial isolates",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative and Gram-positive aerobic and facultative anaerobic bacteria isolates from pure culture, including additional Gram-negative organism groups with Cephalothin panels",
    "fda_folder": "Microbiology"
}